Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume -, Issue -, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-023-01116-8
Keywords
Epistaxis; HHT; Therapeutics; Meta-analysis; Quality of life
Categories
Ask authors/readers for more resources
Propranolol, timolol, tranexamic acid, tamoxifen, and estriol were found to be effective treatments for managing epistaxis in HHT patients. Adverse events of tranexamic acid, tacrolimus, propranolol, and estradiol should be monitored closely.
Purpose of ReviewTo analyze and compare the effects of epistaxis treatments for Hereditary Hemorrhagic Telangiectasia (HHT) patients.Recent FindingsOf total of 21 randomized controlled trials (RCT), the data from 15 RCTs (697 patients, 7 treatments: timolol, propranolol, bevacizumab, doxycycline, tacrolimus, estriol/estradiol, and tranexamic acid) were pooled for the meta-analyses while the other 6 studies (treatments: electrosurgical plasma coagulation, KTP laser, postoperative packing, tamoxifen, sclerosing agent, and estriol) were reviewed qualitatively. When compared to placebo, propranolol offered the most improved epistaxis severity score, mean difference (MD), -1.68, 95% confidence interval (95%CI) [-2.80, -0.56] followed by timolol, MD -0.40, 95%CI [-0.79, -0.02]. Tranexamic acid significantly reduced the epistaxis frequency, MD -1.93, 95%CI [-3.58, -0.28]. Other treatments had indifferent effects to placebo. Qualitative analysis highlighted the benefits of tamoxifen and estriol. The adverse events of tranexamic acid, tacrolimus, propranolol, and estradiol were significantly reported.SummaryPropranolol, timolol, tranexamic acid, tamoxifen, and estriol were effective treatments which offered benefits to HHT patients in epistaxis management. Adverse events of tranexamic acid, tacrolimus, propranolol, and estradiol should be concerned.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available